Proving the Business Case for the Internet of Things

Controlant temperature probe suits digital cold chains

Steve Rogerson
April 16, 2019
 
Iceland-based Controlant, an independent provider of wireless IoT temperature monitoring and automated services for digital cold chains, launched the PR-T80 digital temperature probe at last week’s LogiPharma event in Switzerland.
 
For pharmaceutical products requiring low temperature control and real-time visibility, the probe is designed for dry ice applications, active pharmaceutical ingredients, clinical trials, and additional pharmaceutical and life sciences products that require transport and storage in low temperature-controlled environments.
 
The probe extends the capabilities of Controlant's supply chain monitoring offerings, measuring temperatures between -80 and 0˚C, and automatically sending data to a validated and compliant cloud software platform.
 
Features include: on demand access of data regarding a single shipment or for an entire supply chain; temperature alerts sent by email and SMS; and shipment notifications visible in the Controlant software platform.
 
Business intelligence provides pharmaceutical manufacturers and their supply chain partners with insights to identify and mitigate proactively supply chain risks, ensure quality and compliance, improve supply chain efficiency, and reduce costs.
 
"LogiPharma is the perfect venue for Controlant's launch of its latest innovation," said Gisli Herjolfsson, Controlant’s co-founder and CEO. “Top supply chain disruptors and decision makers from the world's largest pharmaceutical manufacturers gather to share practical insights, best practices and strategies related to end-to-end digital transformation. Through our technology and customer successes, we are eager to help these enterprises transform their temperature-controlled supply chain strategies to adapt to the ever-changing demands while reducing costs, automating quality and compliance, driving efficiency, and implementing customer centricity to enhance their patient-first initiatives."